Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma
Abstract Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET, and AXL. Cabozantinib is approved for the treatment…